Researchers at the National Institutes of Health (NIH) have uncovered new details about how GLP-1 receptor agonists, a widely used class of weight-loss and diabetes medications, affect brain cells to help regulate appetite and body weight.
The findings provide fresh insight into why patients may respond differently to these drugs and why their effectiveness can sometimes decline over time. Scientists believe the research could contribute to the development of more effective treatments for obesity and type 2 diabetes.
In the study, conducted on mice, researchers examined how semaglutide works within neurons, or brain cells. Semaglutide is one of the most commonly prescribed GLP-1 medications and is widely used around the world for weight management and blood sugar control.
Scientists identify key brain mechanisms
Researchers found important signaling pathways and chemical processes inside nerve cells that appear to play a central role in the drug’s weight-loss effects.
According to the study team, these cellular mechanisms may represent the core biological processes responsible for how GLP-1 medications influence appetite and energy balance.
New clues for future obesity treatments
Scientists have long known that GLP-1 drugs act on regions of the brain involved in hunger regulation. However, the precise activity occurring inside targeted brain cells after the medication takes effect remained unclear.
Study co-author Andrew Loutska said researchers previously had only a limited understanding of the internal mechanisms activated within the neurons targeted by these drugs. The new findings, he said, are helping scientists answer important questions about how the medications produce their effects.
Researchers believe the discovery could support the development of next-generation obesity treatments and help improve the effectiveness of existing GLP-1 therapies in the future.
Have You Ever Eaten Banana with Black Pepper? Discover the Benefits
Today's E-Paper